Piper Sandler Initiates Coverage of CareDx with Overweight Rating
Piper Sandler has initiated research coverage on CareDx, Inc. with an "Overweight" rating.
Stocks · News reference
CareDx Chief Financial Officer and Chief Operating Officer Keith Kennedy sold 61,961 shares of company stock on November 5, 2026.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Piper Sandler has initiated research coverage on CareDx, Inc. with an "Overweight" rating.
CareDx, Inc. awarded restricted stock units (RSUs) to 21 new employees as an inducement material to their acceptance of employment.
CareDx, Inc. filed a Form 144 with the SEC on November 5, 2026, as reported by StreetInsider.
CareDx raised its 2026 revenue guidance to $520M-$530M and adjusted EBITDA outlook to $90M-$100M, driven by strong transplant testing demand with volumes up 21% to 50,750. The company's specialty oncology business (NavDx) contributed $12.5M in Q3 revenues with 37% year-over-year growth. Management is preparing new molecular diagnostics AlloHeme and HistoMap Kidney for 2027 commercialization while targeting higher reimbursement rates per test.
CareDx, Inc. announced the publication of a new analysis from its Kidney Allograft Outcomes AlloSure Registry (KOAR) in the journal Transplantation.
Analyst Yi Chen of H.C. Wainwright maintained a 'Neutral' rating on CareDx while increasing the price target from $46 to $90.